Defining early human NK cell developmental stages in primary and secondary lymphoid tissues

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Eissens, Diana N ^a   Spanholtz, Jan ^a   van der Meer, Arnold ^a   van Cranenbroek, Bram ^a   Dolstra, Harry ^a   Kwekkeboom, Jaap ^b   Preijers, Frank W M B ^a   Joosten, Irma ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD33 ANTIGEN; CD56 ANTIGEN; LECTIN RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2A; CD244 PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR; LEUKOCYTE ANTIGEN;

ARTICLE; BLOOD; BONE MARROW; CELL DIFFERENTIATION; CELL HETEROGENEITY; CELL MATURATION; CELL MIGRATION; CONTROLLED STUDY; DEVELOPMENTAL STAGE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; IN VIVO STUDY; INGUINAL LYMPH NODE; LYMPHOID TISSUE; NATURAL KILLER CELL; PROTEIN EXPRESSION; SPLEEN; BIOSYNTHESIS; BONE MARROW CELL; CELL MOTION; CYTOLOGY; IMMUNOPHENOTYPING;

ANTIGENS, CD; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL MOVEMENT; HUMANS; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; LYMPHOID TISSUE; RECEPTORS, IMMUNOLOGIC;

EID: 84856557892     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030930     Document Type: Article

References (37)

1. Robertson MJ, Ritz J, (1990) Biology and clinical relevance of human natural killer cells. Blood 76: 2421-2438.
2. Papamichail M, Perez SA, Gritzapis AD, Baxevanis CN, (2004) Natural killer lymphocytes: biology, development, and function. Cancer Immunol Immunother 53: 176-186.
3. Ljunggren HG, Malmberg KJ, (2007) Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 7: 329-339.
4. Spits H, Lanier LL, Phillips JH, (1995) Development of human T and natural killer cells. Blood 85: 2654-2670.
5. Raulet DH, (1999) Development and tolerance of natural killer cells. Curr Opin Immunol 11: 129-134.
6. Colucci F, Caligiuri MA, Di Santo JP, (2003) What does it take to make a natural killer? Nat Rev Immunol 3: 413-425.
7. Yokoyama WM, Kim S, French AR, (2004) The dynamic life of natural killer cells. Annu Rev Immunol 22: 405-429.
8. Di Santo JP, (2006) Natural killer cell developmental pathways: a question of balance. Annu Rev Immunol 24: 257-286.
9. Freud AG, Becknell B, Roychowdhury S, Mao HC, Ferketich AK, et al. (2005) A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells. Immunity 22: 295-304.
10. Freud AG, Yokohama A, Becknell B, Lee MT, Mao HC, et al. (2006) Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med 203: 1033-1043.
11. Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, et al. (2003) CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 101: 3052-3057.
12. Ferlazzo G, Thomas D, Lin SL, Goodman K, Morandi B, et al. (2004) The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol 172: 1455-1462.
13. Eissens DN, Schaap NP, Preijers FW, Dolstra H, van CB, et al. (2010) CD3(+)/CD19(+)-depleted grafts in HLA-matched allogeneic peripheral blood stem cell transplantation lead to early NK cell cytolytic responses and reduced inhibitory activity of NKG2A. Leukemia 24: 583-591.
14. Shilling HG, McQueen KL, Cheng NW, Shizuru JA, Negrin RS, et al. (2003) Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood 101: 3730-3740.
15. Kobari L, Giarratana MC, Pflumio F, Izac B, Coulombel L, et al. (2001) CD133+ cell selection is an alternative to CD34+ cell selection for ex vivo expansion of hematopoietic stem cells. J Hematother Stem Cell Res 10: 273-281.
16. Freud AG, Caligiuri MA, (2006) Human natural killer cell development. Immunol Rev 214: 56-72.
17. Sivori S, Parolini S, Falco M, Marcenaro E, Biassoni R, et al. (2000) 2B4 functions as a co-receptor in human NK cell activation. Eur J Immunol 30: 787-793.
18. Sivori S, Falco M, Marcenaro E, Parolini S, Biassoni R, et al. (2002) Early expression of triggering receptors and regulatory role of 2B4 in human natural killer cell precursors undergoing in vitro differentiation. Proc Natl Acad Sci U S A 99: 4526-4531.
19. Fathman JW, Bhattacharya D, Inlay MA, Seita J, Karsunky H, et al. (2011) Identification of the earliest natural killer cell-committed progenitor in murine bone marrow. Blood 118: 5439-5447.
20. Crellin NK, Trifari S, Kaplan CD, Cupedo T, Spits H, (2010) Human NKp44+IL-22+ cells and LTi-like cells constitute a stable RORC+ lineage distinct from conventional natural killer cells. J Exp Med 207: 281-290.
21. Nguyen S, Dhedin N, Vernant JP, Kuentz M, Al Jijakli A, et al. (2005) NK cell reconstitution after haploidentical hematopoietic stem cell transplants: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood 105: 4135-4142.
22. Cooley S, Xiao F, Pitt M, Gleason M, McCullar V, et al. (2007) A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self MHC is developmentally immature. Blood 110: 578-586.
23. Cooper MA, Fehniger TA, Caligiuri MA, (2001) The biology of human natural killer-cell subsets. Trends Immunol 22: 633-640.
24. Farag SS, Caligiuri MA, (2006) Human natural killer cell development and biology. Blood Rev 20: 123-137.
25. Wang Y, Xu H, Zheng X, Wei H, Sun R, et al. (2007) High expression of NKG2A/CD94 and low expression of granzyme B are associated with reduced cord blood NK cell activity. Cell Mol Immunol 4: 377-382.
26. Yu J, Mao HC, Wei M, Hughes T, Zhang J, et al. (2009) CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK cell subsets. Blood blood-2009.
27. Dulphy N, Haas P, Busson M, Belhadj S, Peffault de LR, et al. (2008) An unusual CD56(bright) CD16(low) NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation. J Immunol 181: 2227-2237.
28. Braud VM, Allan DS, O'Callaghan CA, Soderstrom K, D'Andrea A, et al. (1998) HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391: 795-799.
29. Kaiser BK, Pizarro JC, Kerns J, Strong RK, (2008) Structural basis for NKG2A/CD94 recognition of HLA-E. Proc Natl Acad Sci U S A 105: 6696-6701.
30. Peruzzi G, Masilamani M, Borrego F, Coligan JE, (2009) Endocytosis as a mechanism of regulating natural killer cell function: unique endocytic and trafficking pathway for CD94/NKG2A. Immunol Res 43: 210-222.
31. Moroso V, Metselaar HJ, Mancham S, Tilanus HW, Eissens D, et al. (2010) Liver grafts contain a unique subset of natural killer cells that are transferred into the recipient after liver transplantation. Liver Transpl 16: 895-908.
32. Thomson AW, Knolle PA, (2010) Antigen-presenting cell function in the tolerogenic liver environment. Nat Rev Immunol 10: 753-766.
33. Dalle JH, Menezes J, Wagner E, Blagdon M, Champagne J, et al. (2005) Characterization of cord blood natural killer cells: implications for transplantation and neonatal infections. Pediatr Res 57: 649-655.
34. Tanaka H, Kai S, Yamaguchi M, Misawa M, Fujimori Y, et al. (2003) Analysis of natural killer (NK) cell activity and adhesion molecules on NK cells from umbilical cord blood. Eur J Haematol 71: 29-38.
35. Spanholtz J, Tordoir M, Eissens D, Preijers F, van der MA, et al. (2010) High Log-Scale Expansion of Functional Human Natural Killer Cells from Umbilical Cord Blood CD34-Positive Cells for Adoptive Cancer Immunotherapy. PLoS ONE 5: e9221.
36. Zhao XY, Huang XJ, Liu KY, Xu LP, Liu DH, (2007) Reconstitution of Natural Killer Cell Receptor Repertoires after Unmanipulated HLA-Mismatched/Haploidentical Blood and Marrow Transplantation: Analyses of CD94:NKG2A and Killer Immunoglobulin-Like Receptor Expression and Their Associations with Clinical Outcome. Biol Blood Marrow Transplant 13: 734-744.
37. Male V, Hughes T, McClory S, Colucci F, Caligiuri MA, et al. (2010) Immature NK cells, capable of producing IL-22, are present in human uterine mucosa. J Immunol 185: 3913-3918.